Zogenix, Inc. (ZGNX)

Trade ZGNX now with
2/6/2018 8:06:57 AM Zogenix Reports Receipt Of FDA Breakthrough Therapy Designation For ZX008 In Dravet Syndrome
12/1/2017 2:51:57 AM In The Spotlight: Zogenix
11/29/2017 8:06:19 AM Zogenix Initiates Phase 3 Trial For ZX008 In Lennox-Gastaut Syndrome
11/21/2017 8:14:47 AM Zogenix To Present New Data From Phase 3 Trial Of ZX008 In Dravet Syndrome (Study 1)
10/2/2017 8:35:12 PM Zogenix Prices Underwritten Public Offering Of 6.70 Mln Shares At $37.50/shr
10/2/2017 6:54:57 AM Zogenix Proposes 4.3 Mln Shares In An Underwritten Public Offering
9/29/2017 7:06:56 AM Zogenix Reports Positive Top-line Results From Pivotal Phase 3 Trial Of ZX008 In Dravet Syndrome
6/22/2017 8:03:11 AM Zogenix Receives Orphan Drug Designation From FDA For ZX008 In Treatment Of Lennox Gastaut Syndrome
3/1/2017 8:07:37 AM Zogenix Gets Orphan Drug Designation In European Union For ZX008 In Lennox Gastaut Syndrome